Satraplatin and Bevacizumab in Treating Patients With Metastatic Prostate Cancer Previously Treated With Docetaxel

Inclusion criteria

DISEASE CHARACTERISTICS: * Histologically confirmed adenocarcinoma of the prostate, meeting the following criteria: * Metastatic disease * Objective progression or rising prostate-specific antigen (PSA) despite androgen-deprivation therapy and antiandrogen withdrawal * Patients with rising PSA must demonstrate a rising trend with 2 successive elevations at a minimum interval of 1 week * Minimum PSA of 5 ng/mL or new areas of bony metastases on bone scan required if no measurable disease * No minimum PSA for measurable disease * Must have received ≤ 1 prior docetaxel-based chemotherapy for metastatic disease * No known CNS disease or brain metastases * Testosterone \< 0.5 ng/mL (castrate level) * Concurrent luteinizing-hormone releasing-hormone agonist allowed to maintain castrate level PATIENT CHARACTERISTICS: * Zubrod performance status 0-1 * Life expectancy ≥ 12 weeks * Absolute neutrophil count ≥ 1,500/mm³ * Platelet count ≥ 100,000/mm³ * Hemoglobin ≥ 8.0 g/dL * Bilirubin normal * Creatinine ≤ 2 mg/dL OR creatinine clearance ≥ 50 mL/min * Urine protein:creatinine ratio ≤ 1.0 OR proteinuria ≤ 2+ by urine dipstick OR ≤ 1 g protein/24-hour urine collection * Fertile patients must use effective contraception during and for ≥ 6 months after completion of study treatment * No significant traumatic injury within the past 28 days * Adequately controlled hypertension (defined as systolic blood pressure \[BP\] ≤ 150 mm Hg and/or diastolic BP ≤ 100 mm Hg on antihypertensive medications) * No history of hypertensive crisis or hypertensive encephalopathy * No New York Heart Association class II-IV congestive heart failure * No myocardial infarction or unstable angina within the past 6 months * No stroke or transient ischemic attack within the past 6 months * No significant vascular disease (e.g., aortic aneurysm, aortic dissection) * No symptomatic peripheral vascular disease * No evidence of bleeding diathesis or coagulopathy * No prior malignancy except adequately treated skin cancer or any other cancer in complete remission for ≥ 2 years * Able to swallow and retain capsules * No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months * No serious nonhealing wound, ulcer, or bone fracture * No known hypersensitivity to any component of bevacizumab * No history of allergic reactions attributed to compounds of similar chemical or biological composition to bevacizumab * No uncontrolled intercurrent illness, including, but not limited to, any of the following: * Ongoing or active infection * Symptomatic congestive heart failure * Unstable angina pectoris * Cardiac arrhythmia * No psychiatric illness or social situation that would preclude compliance with study requirements * No HIV positivity * No immune deficiency PRIOR CONCURRENT THERAPY: * See Disease Characteristics * More than 4 weeks since prior flutamide * More than 6 weeks since prior bicalutamide or nilutamide * At least 4 weeks since prior radiotherapy * At least 2 weeks since prior minor surgery * More than 7 days since prior core biopsy or minor surgery (excluding placement of a vascular access device) * More than 28 days since prior major surgery or open biopsy (8 weeks if high-risk procedure such as liver resection, thoracotomy, or neurosurgery) * Concurrent low-dose aspirin (≤ 325 mg/day) allowed * Concurrent anticoagulants allowed if patient has been on therapy ≥ 4 weeks and has no acute thromboembolic activity * No concurrent major surgery * No concurrent aprepitant * No concurrent immunosuppressive therapy * No concurrent combination anti-retroviral therapy for HIV-positive patients * No other concurrent antitumor therapy (including radiotherapy) * No other concurrent investigational agents